

## PRESS RELEASE

---

Caen, October 24<sup>th</sup> 2024

### H.A.C.Pharma announces the acquisition from Sanofi of the drug product TROPHICREME<sup>®</sup>

The French pharmaceutical company H.A.C.Pharma continues its growth strategy and strengthens its portfolio of drugs with significant therapeutic added value through the acquisition of the gynecology specialty product TROPHICREME<sup>®</sup> (estriol) from Sanofi.

H.A.C.Pharma offers patients a diversified portfolio of essential medicines, orphan drugs and life-saving treatments. The group markets thirty specialty medicines in eight different therapeutic areas, including gynecology.

H.A.C.Pharma is recognized for its support to patients in the diagnosis and understanding of their illness, its treatment and therapeutic compliance. To achieve this, H.A.C.Pharma develops new formulations and compliance tools, manages the supply of its product portfolio, takes care of pharmacovigilance monitoring and promotes the proper use of its medicines through its own sales force in France. H.A.C.Pharma also has a network of distributors in different European countries for some of its key drugs.

Along with the founder and majority shareholder Philippe Bissay, the new management team has implemented an intensive search for product acquisitions and in-licensing to expand its portfolio. Supported by Turenne Santé and BNPP Développement, which acquired a stake in the company in January 2022, H.A.C.Pharma wishes to continue expanding its range of products and territories.

**Philippe Bissay, Chairman and CEO of H.A.C.Pharma, declares:** *“This acquisition is the first since the arrival of Turenne Santé and BNP Paribas Développement at my side in 2022. It rewards the work of our teams and validates our development strategy in France and Europe, based on partnerships with international healthcare companies, the acquisition of proven molecules and the launch of innovative products under license. It is also the result of close collaboration with our banks: BNP, Arkéa, Caisse d’Épargne and BPI.”*

**Mounia Chaoui and Paul Chamoulaud, Turenne Santé, indicate:** *“We are delighted with this first acquisition and the confidence of Sanofi’s teams. This product strengthens H.A.C.Pharma’s positioning in a therapeutic indication that it knows well. We want to continue and significantly expand our product portfolio.”*

**Frédéric Connault, BNP PARIBAS Développement, specifies:** *“We are very pleased with this acquisition, the first cornerstone in the transformation of H.A.C. Pharma into a key player in hospital and specialty prescription drugs. We wish to continue our efforts in this direction.”*

---

**CONTACTS PRESSE**

Delphine Granier – Turenne Groupe  
dgranier@turennecapital.com  
06 33 05 48 50

H.A.C.Pharma  
communication@hacpharma.com  
02 31 47 92 46

---

---

## ABOUT H.A.C. PHARMA

H.A.C. Pharma is a French pharmaceutical laboratory based in Caen. Founded in 2007, H.A.C. Pharma, an independent laboratory, works to maintain and make available drugs with significant therapeutic added value. H.A.C. Pharma markets prescription drugs in Europe, in various therapeutic areas such as gynecology, oncohematology, neuropsychiatry, endocrinology and gastroenterology.

Health actor, present alongside patients and health professionals, H.A.C. Pharma is recognized for promoting the proper use of its pharmaceutical specialties. In particular thanks to its promotion, medical information and pharmacovigilance monitoring teams.

H.A.C. Pharma is pursuing its growth strategy in France and Europe via three areas of development: collaboration with international laboratories for the marketing of their drugs, the acquisition of mature molecules and the launch of innovative products under license.

[www.hacpharma.com](http://www.hacpharma.com)

---

## ABOUT TURENNE GROUPE

**Independent leader in small cap private equity in France**, Turenne Groupe has been supporting entrepreneurs for 25 years, via its management companies, in their innovation, development and transfer projects of their company throughout the country.

With nearly 2 billion euros in assets under management and +300 companies in its portfolio, Turenne Groupe relies on sectoral expertise with dedicated teams in the health, engineering and environmental services sectors. , deeptech, hotels, as well as specific expertise (debt funds and funds with reinforced CSR criteria).

Present throughout France with 7 regional locations (Paris, Lille, Lyon, Marseille, Nice, Bordeaux and Nantes) and regional funds, Turenne Groupe has 85 employees, half of whom are in the region.

A mission-driven company since 2023, and 100% owned by its employees, Turenne Groupe actively supports its portfolio companies in their CSR approach by strongly promoting the sharing of value creation. Turenne Groupe also finances and runs the Béatrice Denys Foundation for therapeutic innovation.

[www.turennecapital.com](http://www.turennecapital.com)

---

## ABOUT BNP PARIBAS DEVELOPPEMENT

BNP Paribas Développement, an independent subsidiary of the international banking group BNP Paribas, is a public limited company which has, for over 30 years, invested its own funds directly as a minority shareholder to support the development of successful SMEs & ETIs and ensure their sustainability by facilitating their transmission. Beyond the financial resources made available to the company to ensure stable resources, the vocation of BNP Paribas Développement is to support the management team over the long term in carrying out its medium-term strategic projects. Our minority positioning ensures our partners appropriate governance without interference in day-to-day management, while benefiting from the strength of a recognized group and the experience of a partner with a portfolio of more than 400 diversified holdings representing more than of €2000 million invested.